NumerixS Investment Technologies Inc purchased a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the first quarter, according to its most recent filing with the SEC. The firm purchased 15,000 shares of the biotechnology company’s stock, valued at approximately $190,000.
Several other large investors also recently made changes to their positions in IRWD. Gotham Asset Management LLC bought a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $135,000. Bank of Montreal Can lifted its holdings in shares of Ironwood Pharmaceuticals by 426.9% during the 4th quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 13,649 shares during the period. Financial Counselors Inc. bought a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth about $204,000. Amalgamated Bank bought a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $211,000. Finally, Perennial Advisors LLC bought a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth about $243,000. Institutional investors and hedge funds own 99.22% of the company’s stock.
In other news, CFO Gina Consylman sold 4,055 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $10.53, for a total transaction of $42,699.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is owned by insiders.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.10). The business had revenue of $68.73 million for the quarter, compared to analysts’ expectations of $81.93 million. The company’s quarterly revenue was down .6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.25) EPS. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post -0.11 EPS for the current fiscal year.
A number of equities analysts have recently commented on the stock. BTIG Research set a $19.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 14th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. GMP Securities raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “neutral” rating and lifted their price target for the company from $11.50 to $14.00 in a report on Monday, February 25th. BidaskClub downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 25th. Finally, Wood & Company began coverage on shares of Ironwood Pharmaceuticals in a report on Tuesday, February 26th. They set a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $15.15.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Featured Article: What are no-load funds?
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.